Johnson & Johnson

Johnson & Johnson and Momenta Pharmaceuticals lawsuit alleges infringement of two old patents associated with 20mg/ml and 40mg/ml Glatiramer Acetate injection, Natco said in a regulatory filing.

Johnson & Johnson is suspending sales forecasts for its COVID-19 vaccine only a few months after saying the shot could bring in as much as $3.5 billion this year.

J&J had previously said it would pause enrollment in clinical trials in Russia, Ukraine and Belarus but was committed to providing essential health products

Delivery delays and an uneven demand during last year resulted in the drugmaker narrowly missing its goal of garnering $2.50 billion in vaccine sales in 2021.

Most Americans should be given the Pfizer or Moderna vaccines instead of the Johnson & Johnson shot that can cause rare but serious blood clots, US health advisers recommended

It's an unusual move and the CDC's director, Dr. Rochelle Walensky, must decide whether to accept the panel's advice

Vaccine advisers with the US CDC will meet on Thursday to discuss potentially limiting the use of the Johnson and Johnson vaccine due to persistent blood clot issues

The health-care giant will split off its consumer division in 18 to 24 months, the company said in a statement

Johnson & Johnson said it will break itself up into two public companies, one focused on drugs and medical devices, and the other on consumer products

Emergent BioSolutions played a role in the Trump administration's effort to speed up vaccine development and distribution

Pfizer and BioNTech said a booster shot of their Covid-19 vaccine restored full protection in a large study, results that are likely to bolster the argument for giving a third dose more widely

J&J's single-shot vaccine is made with a different technology than the two-shot Pfizer and Moderna vaccines -- and it has consistently shown lower effectiveness levels

The FDA panel will meet on Thursday and Friday to weigh the evidence for booster doses

SEC asks J&J to monitor adverse events closely for next three months

Drug cuts hospitalisation, deaths by 50%, shows an analysis of a late-stage trial

J&J said a booster given two months after the first dose increased antibody levels four to six-fold

According to sources, discussions are on between J&J and the Centre on the matter of indemnity against any serious adverse effect after vaccination

The company said on Friday that it had submitted an application to the Central Drugs Standard Control Organisation (CDSCO) on August 17 in this regard

To achieve herd immunity, studies have to be done on children, pharma major says

Duato, 59, currently serves as vice chairman of J&J's executive committee